The gene therapy era has arrived. So have the challenges.
Biopharma in 2019
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape. Κάντε like … Continue Reading Ash 2018 preview – blood cancers offer biotech a chance at redemption
Is the Biotech Bull Market Over?
Gene therapy deal-making shows no signs of stopping
10 biotechs set to shake up the industry’s top ranks
Looking ahead to 2018, the most promising products in pharma’s pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with … Continue Reading The 2018 pipeline report: Aspiring assets to keep an eye on
Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno … Continue Reading What do the CAR-T Patient Deaths Mean for the Future of the Field?